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We have identified three open reading frames (ORFs) in murine cytomegalovirus (MCMV), designated M82,
M83, and M84, which likely encode homologs of the human cytomegalovirus (HCMV) UL82 and UL83 matrix
phosphoproteins. These ORFs, in the HindIII C fragment of MCMV, are colinear with the UL82, UL83, and
UL84 ORFs of HCMV. M82 encodes a 598-amino-acid (aa) protein with homology to UL82, M83 encodes an
809-aa protein with homology to UL82 and UL83, and M84 encodes a 587-aa protein with homology to UL83
and UL84. Analysis of transcription by Northern (RNA) blotting indicated that the M82 and M83 ORFs are
transcribed as 2.2- and 5-kb mRNAs, respectively, at 24 to 48 h postinfection (p.i.), while M84 is transcribed
as a 6.9-kb mRNA only at 8 h p.i. All transcripts appear to terminate at the same position 3* of the M82 ORF.
Of the products of the three ORFs, only M83 is strongly recognized by hyperimmune mouse serum. The M83
protein is a virion-associated phosphoprotein with an apparent molecular mass of 125 kDa. In MCMV-infected
cells, it is detectable by Western blotting (immunoblotting) only at 48 h p.i. in the absence of phosphonoacetic
acid, consistent with late gene expression. The M83 ORF is also expressed at high levels in cells infected by a
recombinant vaccinia virus and yields a protein which is serologically cross-reactive and comigrates with the
authentic MCMV protein in sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Human cytomegalovirus (HCMV) is the major viral cause of
birth defects in newborns and poses serious problems in indi-
viduals with impaired immune function (24). The severe dis-
ease resulting from infection with this virus has provided a
strong impetus for studies directed toward its prevention and
treatment. Although there have been significant advances in
our knowledge of the molecular biology of HCMV in vitro,
investigation of the in vivo pathogenesis and immunology has
been limited by the strict species specificity of the virus. To
circumvent this limitation, cytomegaloviruses of other species,
in particular murine cytomegalovirus (MCMV), have been
used as models of the human infection (5, 24, 41, 67, 68).
In the last 15 years, our understanding of the cell-mediated
immune response to MCMV infection has expanded signifi-
cantly. Early work by Koszinowski and colleagues demon-
strated that cytotoxic T lymphocytes (CTLs) generated in
BALB/c mice were directed against both structural and non-
structural viral antigens, although a major fraction was specific
for antigens expressed at immediate-early times during infec-
tion (29–31, 54, 55, 69). The dominant CTL class was directed
against the 89-kDa IE1 (immediate-early 1) phosphoprotein,
designated pp89. Vaccination of BALB/c mice with recombi-
nant vaccinia viruses expressing this protein generated some
protective immunity, as evidenced by increased resistance to
the lethal effects of subsequent MCMV challenge (28). Pro-
tection was mediated entirely by CD81 lymphocytes. However,
it is important to note that protective immune mechanisms in
addition to CD81 antiviral effector cells are induced following
MCMV infection (28, 53, 56–58).
Although the immune response to HCMV infection is less
well defined, several recent findings have yielded important
clues for deciphering key targets of the cell-mediated immune
response. Particularly notable are studies showing that
HCMV-seropositive individuals possess relatively low levels of
CD81 CTL specific for both the HCMV IE1 72-kDa protein,
a functional homolog of the MCMV pp89, and the structural
glycoprotein B (3). The bulk of HCMV-specific CTLs are
directed against a subset of viral antigens introduced into the
host cell during viral penetration (20, 59). The HCMV UL83
(pp65) matrix phosphoprotein appears to be the major target
of these CTLs, as well as a dominant target of proliferative
responses by CD41 T lymphocytes (1, 17, 38). The clinical
application of these findings has already generated much ex-
citement. Although the absolute number of trials is still small,
there is increasing evidence that matrix protein-specific CTLs
can be isolated from HCMV-seropositive bone marrow do-
nors, propagated in vitro, and adoptively transferred to immu-
nodeficient bone marrow recipients, conferring protection
against HCMV viremia and pneumonia (60, 70).
In addition to UL83, the HCMV virion contains at least
three other proteins, designated UL32 (pp150), UL82 (pp71),
and UL99 (pp28), which are localized to the matrix of the viral
particle and induce strong humoral immune responses in in-
fected individuals (26, 27, 33–35, 40, 45, 51, 72). Recognition of
the key role played by this class of proteins in protective im-
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mune responses has provided a strong impetus for studies to
determine whether similar mechanisms function in the murine
model. If such is the case, studies of MCMV may yield insights
into the properties of the matrix-specific immune response
unobtainable in the more unwieldy experimental context of
HCMV.
As a prerequisite for establishing the immunological role of
MCMV matrix proteins, we initiated studies to identify the
MCMV gene products homologous to the HCMV matrix pro-
teins. The first such gene identified represented the MCMV
homolog of the HCMV 28-kDa matrix phosphoprotein
(UL99) (9). In this report, we used a similar strategy to identify
and characterize MCMV open reading frames (ORFs) encod-
ing likely homologs of the HCMV UL82 and UL83 matrix
phosphoproteins. On the basis of the colinearity of recently
identified MCMV genes with their HCMV counterparts, we
selected subgenomic fragments of MCMV for sequencing (8, 9,
12, 41). In this way, we were able to identify a region of MCMV
HindIII fragment C containing ORFs which displayed colin-
earity and significant homology with the UL86 major capsid
protein, the UL85 putative capsid protein, and the UL82 and
UL83 matrix phosphoproteins of HCMV (7, 8, 27, 39, 63, 65).
Additionally, one ORF was identified in a position colinear
with and possessing weak homology to the nonstructural
HCMV UL84 protein (23). This ORF, however, possessed
much stronger homology to UL83 than to UL84. We describe
here the temporal kinetics and pattern of transcription from
this region and analyze in detail the protein product of the
MCMV M83 ORF, a UL82/UL83 homolog, which generates a
strong humoral immune response during MCMV infection. In
addition, we show that the M83 ORF can be efficiently ex-
pressed by a recombinant vaccinia virus.
MATERIALS AND METHODS
Cells and viruses. NIH 3T3 cells (ATCC CRL 1658) were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% calf serum, glutamine (0.29
mg/ml), penicillin (200 U/ml), streptomycin (0.2 mg/ml), gentamicin (0.05 mg/ml)
and amphotericin B (1.5 mg/ml).
The K181 strain of MCMV was used in all experiments. Salivary gland stocks
of virus were prepared following intraperitoneal inoculation of female BALB/c
mice as previously described (12). Uninfected salivary glands for mock infection
were prepared in an identical manner. Tissue culture MCMV was prepared by
infection of NIH 3T3 cells at a multiplicity of infection of 0.01 to 0.05. The
infection was allowed to proceed until cytopathic effect was 100%, at which point
the medium was changed. After 3 days, the supernatant was harvested and
supplemented with dimethyl sulfoxide to a final concentration of 1%. Titers of
the virus stocks were determined by plaque assay, and the virus stocks were
stored at 2708C until use. MCMV was purified from extracellular tissue culture
medium by density gradient centrifugation as previously described (9).
Recombinant DNA clones. Unless otherwise noted, enzymes were obtained
from Bethesda Research Laboratories, Inc., and used as recommended by the
manufacturer. A 14.2-kbp HindIII-StuI subfragment of MCMV HindIII frag-
ment C (39) was subcloned from pACYC184-H3C into HindIII- and SmaI-
cleaved pGEM1 (Promega Biotech, Inc.) to form H3C14.2-GEM. A 2.2-kbp StuI
subfragment of the HindIII fragment C, representing the fragment adjacent to
the 14.2-kbp HindIII-StuI subfragment, was subcloned into SmaI-cleaved
pGEM1 to form H3C2.2-GEM. A clone was selected in which the end of the
2.2-kbp fragment adjacent to the 14.2-kbp fragment was located proximal to the
EcoRI site of pGEM1. H3C14.2-GEM was cut with PstI, and a 2.1-kbp subfrag-
ment, encoding the N-terminal 669 amino acids of the M83 ORF, was isolated
and subcloned into PstI-cleaved pGEM1 to form M83(Pst)-GEM. The 59 end of
the putative M83 ORF was proximal to the XbaI site of pGEM1, while the 39 end
was proximal to the HindIII site. A 3-kbp KpnI subfragment of H3C14.2-GEM,
containing all of the M83 ORF except the N-terminal 69 amino acids, was
isolated, blunt ended, and ligated into SmaI-cleaved pGEM1 to form the clone
H3C3-GEM. A clone with the 39 end of the putative M83 ORF proximal to the
EcoRI site in the polylinker of pGEM1 was selected. M83(Pst)-GEM was cleaved
with XbaI and HindIII, and a 2.1-kbp subfragment was isolated and ligated to
XbaI- and HindIII-cleaved pGEX-KG (21) to form M83-GEX. H3C3-GEM was
cleaved with EcoRI and PstI, and a 1.1-kbp subfragment isolated and ligated to
EcoRI- and PstI-cleaved pGEM1, forming 39M83-GEM. M83-GEX was cleaved
with PstI, and a 2.1-kbp subfragment was isolated and ligated to PstI-cleaved
39M83-GEM, forming M83(Whole)-GEM. The orientation of the PstI fragment
in M83(Whole)-GEM reconstructed the genomic orientation. M83(Whole)-
GEM was cleaved withHindIII, XbaI, andDraI (New England Biolabs, Inc.), and
a 3.1-kbp fragment, containing the entire M83 ORF, was isolated. This fragment
was either ligated directly to the HindIII- and XbaI-cleaved eukaryotic expres-
sion plasmid pcDNA3 (Invitrogen), yielding pcDNA3-M83, or blunt ended and
ligated to the SmaI-cleaved vaccinia vector pSC11 (a gift of B. Moss), yielding
pSC11-M83.
A 3-kbp EcoRV fragment of pACYC184-H3C, containing the entire M82
ORF, was isolated and ligated to SmaI-cleaved pGEM1, yielding H3C(RV)-
GEM. The 59 end of the M82 ORF was proximal to the EcoRI site of pGEM1.
To place an EcoRI site just 59 of the initiating codon of the M82 ORF,
H3C(RV)-GEM was cut with EcoRI and BglII and a 5.3-kbp fragment, contain-
ing the vector and the entire M82 ORF 39 of a BglII site 328-bp downstream from
the initiating methionine codon, was isolated. To reconstruct the 59 0.33 kbp of
the M82 ORF, PCR was performed, using as the template H3C(RV)-GEM and
as primers 59-M82 PCR (59-GAA TTC ATG GCC GAG GAA TTT-39) and
39-M82 PCR (59-AGG TGG CTG TCG TTC AGC TC-39) (Oligos Etc.). Stan-
dard PCR mixtures, supplemented with 2 mM MgCl2, were prepared with or
without template DNA, using the materials in the GeneAmp PCR reagent kit
(Perkin-Elmer) and following the manufacturer’s recommendations. Twenty-five
cycles of PCR were carried out (1 min at 948C, 1 min at 508C, and 1 min at 728C,
followed by 10 min at 728C). A 471-bp product, synthesized only in the presence
of template DNA, was digested with EcoRI and BglII, and a 0.33-kbp product
was isolated and ligated to the 5.3-kbp EcoRI- and BglII-cleaved H3C(RV)-
GEM, yielding M82-GEM. Both strands of the PCR product were sequenced.
M82-GEM was then cut with EcoRI and XbaI, and a 2.5-kbp fragment, contain-
ing the entire M82 ORF, was isolated and ligated to EcoRI- and XbaI-cleaved
pcDNAI/Amp (Invitrogen), yielding pcDNAI-M82. The 59 end of the M82 ORF
was proximal to the EcoRI site of pcDNAI/Amp. pcDNAI-M82 was next cut with
EcoRI and XbaI, and a 2.5-kbp fragment was isolated and ligated to EcoRI- and
XbaI-cleaved pcDNA3, yielding pcDNA3-M82. The 59 end of the M82 ORF was
proximal to the EcoRI site of pcDNA3.
H3C14.2-GEM was digested with HindIII and KpnI, and an 8.2-kbp KpnI
subfragment was isolated and subcloned into KpnI-cleaved pGEM4Z (Promega
Biotech), yielding H3C8.2-GEM. A clone which had the 59 end of the M86 ORF
proximal to the HindIII site of the vector was selected. H3C8.2-GEM was
cleaved with Eco47III (New England Biolabs) and NotI, and a 5.4-kbp subfrag-
ment, containing vector sequences, the M84 ORF, and some additional material
59 of the M86 ORF, was isolated and recircularized, yielding pGEM-iM84.
pGEM-iM84 was digested with BamHI, and a 4.6-kbp subfragment, containing
vector sequences and all of the M84 ORF 39 from a BamHI site 0.13 kbp
downstream from the putative initiating methionine codon of the ORF, was
isolated and recircularized to yield pGEM-iM84/2. To reconstruct the 59 0.13 kbp
of the M84 ORF, PCR was performed, using as the template pGEM-iM84 and
as primers 59-M84 PCR (59-CGG GAT CCT TCG ACA TGT CGG TCA ACG
TTT ACT TGC CG-39) and 39-M84 PCR (59-GAA GAT CTC GGT CTG GAG
GAA TTT GGT CTC GTA GGG GC-39) (Integrated DNA Technologies,
Coralville, Iowa). Standard PCR mixtures were prepared as described above.
Thirty cycles of PCR were carried out (1 min at 948C, 1 min at 608C, and 1 min
at 728C, followed by 10 min at 728C). A 150-bp product, synthesized only in the
presence of the DNA template, was isolated, digested with BamHI and BglII, and
cloned into BamHI-cut pGEM-iM84/2, yielding pGEM-M84. The BamHI end of
the PCR product was proximal to the vector, while the BglII end was proximal to
the M84 ORF. This recreated the M84 ORF with a BamHI site immediately 59
of the initiating methionine codon. The internal BamHI site of M84 was de-
stroyed, and amino acid 44 of the encoded protein was changed from glycine to
glutamate. Both strands of the PCR product were sequenced. A 2-kbp BamHI-
EcoRI subfragment of pGEM-M84 was then subcloned into BamHI- and EcoRI-
cut pcDNA3, yielding pcDNA3-M84.
The vaccinia virus vector pGS62-pp89 (a gift of U. Koszinowski), encoding the
MCMV pp89, was cleaved with EcoRI, and a 1.8-kbp fragment was isolated and
ligated to EcoRI-cleaved pcDNA3, yielding pcDNA3-pp89 (28, 69). The 59 end
of the pp89-encoding insert was proximal to the HindIII site of pcDNA3.
DNA sequencing and data analysis. Sequencing of the Smith strain of MCMV
is described elsewhere (52). The M83 region of the K181 strain MCMV genome
was sequenced from either M13 subclones of the region or denatured double-
stranded DNA templates by the dideoxynucleotide chain termination method
(64), using protocols and reagents supplied with the Sequenase version 2.0 DNA
sequencing kit (United States Biochemical) and the T7 or SP6 promoter primer
(Promega Biotech) or synthetic oligonucleotides (Oligos Etc.) as primers. Both
strands were completely sequenced.
Analysis of sequence overlaps, open reading frames and homologies was done
by computer, using the programs DNA Inspector IIe (Textco) and FASTA (49,
50). Analysis of phylogenetic relationships between ORFs was also done by
computer using the programs inspect, Progressive Alignment, Tree, and noneg
(11, 13, 14).
Preparation of recombinant GST and GST-M83 fusion proteins. The DH5a
strain of Escherichia coli (Gibco BRL) was transformed with pGEX-KG (21) or
M83-GEX as recommended by the manufacturer. Recombinant glutathione
S-transferase (GST) and GST-M83 proteins were purified from transformed
bacteria by affinity chromatography using glutathione-agarose beads as previ-
ously described (9).
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Preparation of normal and hyperimmune mouse serum and anti-GST-M83
rabbit serum. Normal and hyperimmune anti-MCMVmouse sera were prepared
as previously described (9). To generate immune rabbit serum against GST-M83,
a naive female New Zealand White rabbit was bled from the ear vein, and serum
was prepared and adsorbed from the blood as described below. After confirma-
tion by Western blot (immunoblot) analysis of the animal’s lack of reactivity
against GST-M83, the rabbit was primed by intramuscular and subcutaneous
injection of 350 mg of purified GST-M83 in Freund’s complete adjuvant. Booster
doses of 70, 175, and 270 mg of purified GST-M83 were given at weeks 3, 6, and
20, respectively, by intramuscular and subcutaneous injection in Freund’s incom-
plete adjuvant. At week 22, blood was obtained and serum was prepared as
described below. Serum obtained at 22 weeks was found to be strongly positive
by Western blot analysis for reactivity against the GST-M83 protein and was used
in the experiments described herein.
Sera were prepared, adsorbed, and purified as described by Harlow and Lane
(22) and stored at 2208C. All sera were adsorbed twice with an acetone powder
derived from an induced culture of pGEX-KG-containing E. coli DH5a. After
adsorption, hyperimmune mouse and rabbit anti-GST-M83 sera were further
purified by ammonium sulfate precipitation. Purified sera were stored as 50%
glycerol stocks at 2208C.
Production of recombinant vaccinia viruses. Recombinant vaccinia viruses
expressing M83 and b-galactosidase proteins were constructed by using the
vaccinia virus vector plasmids pSC11-M83 and pSC11, respectively, the WR
strain of vaccinia virus as the parent virus (ATCC VR-119), and methods pre-
viously described (6, 9). The resulting recombinant viruses were designated
M83-vacc and pSC11-vacc, respectively.
Analysis of infected cell RNA. Polyadenylated RNA was isolated from unin-
fected NIH 3T3 cells or at 8 h (early), 24 h (midpoint), or 48 h (late) after
infection of confluent NIH 3T3 cells at a multiplicity of infection of 2 PFU per
cell. Total RNA was isolated by using the RNAgents total RNA isolation system
(Promega) or the Total RNA kit (Qiagen) according to the manufacturers’
recommendations. Polyadenylated RNA was isolated from the total RNA prep-
arations by using either the PolyATtract mRNA isolation system (Promega) or
the Oligotex mRNA isolation kit (Qiagen) according to the manufacturers’
recommendations, subjected to electrophoresis through 1 or 1.2% agarose-form-
aldehyde gels (15), transferred to a Nytran (Schleicher & Schuell) membrane,
and probed with 32P-labeled oligonucleotide or double-stranded DNA probes.
Four oligonucleotides were synthesized (Integrated DNA Technologies) for use
as probes: 59-M86 (59-GCA GCA GCT CCG TCG CCG TCC AGT TCT CCC-
39), 59-M85 (59-CCC CGG TCG TGA GGC GCT GCT CGA ACG TGA-39),
59-M83 (59-AGT GCC ACC TGG GTG AGG GGA GCG ACG CCG-39), and
39-M82 (59-TAC CGC CGG GAA ATT GGT GAA TGC TTC GTG-39). Oli-
gonucleotide probes were labeled by using T4 polynucleotide kinase and
[g-32P]ATP (ICN). An 837-bp BamHI-SmaI subfragment of pcDNA3-M84 and
a 682-bp EcoRI-PstI subfragment of H3C2.2-GEM, designated M84 and M82,
respectively, were isolated and labeled by random hexamer priming with
[a-32P]dCTP (ICN), using the the Random Primers DNA labeling system
(Gibco) according to the manufacturer9s recommendations.
Preparation of infected cell proteins. Proteins from mock-infected NIH 3T3
cells or those infected with salivary gland-passaged MCMV K181 strain were
prepared at the same time points and in the presence of the same drugs as
previously described (9). These protein extracts were used to study the kinetics
of M83 protein expression.
In the experiment in which vaccinia virus-expressed proteins were compared
with proteins in MCMV-infected cells, MCMV-infected NIH 3T3 cell lysates
were prepared at 48 h postinfection (p.i.). Proteins from these cells, as well as
uninfected NIH 3T3 cells, were then harvested as described previously (71).
Protein extracts from vaccinia virus-infected cells were prepared in an identical
manner at 75 h after infection of NIH 3T3 cells with M83-vacc or pSC11-vacc at
a multiplicity of infection of 5.
Protein electrophoresis, Western blot analysis, and in vitro transcription-
translation. Proteins were subjected to sodium dodecyl sulfate (SDS)-polyacryl-
amide gel electrophoresis (PAGE) essentially as described by Laemmli (32). Ten
percent mini-SDS-polyacrylamide gels were run, using the Mini-PROTEAN II
system (Bio-Rad). Following electrophoresis, gels were transferred to nitrocel-
lulose for Western analysis. Proteins were visualized by staining the nitrocellu-
lose with amido black (Sigma N-9002) and photographed. The blots were then
subjected to Western analysis using the ECL system (Amersham) according to
the manufacturer’s recommendations. Unless otherwise noted, primary mouse
and rabbit antisera were used at a 1:1,000 dilution and horseradish peroxidase-
conjugated anti-mouse or anti-rabbit immunoglobulin antiserum (Amersham)
was used as secondary antiserum at a 1:3,000 dilution.
Plasmids pcDNA3, pcDNA3-M82, pcDNA3-M83, pcDNA3-M84, and
pcDNA3-pp89 were used as substrates for in vitro transcription-translation re-
actions, using the TNT Coupled Reticulocyte Lysate system (Promega) accord-
ing to the manufacturer’s recommendations. T7 RNA polymerase was used for
transcription. Reactions were carried out either in the presence or in the absence
of [35S]methionine (Amersham SJ1015). Labeled reactions were separated on
10% mini-SDS-polyacrylamide gels, stained for total proteins with Coomassie
brilliant blue, treated with Fluoro-Hance (Research Products International,
Mount Prospect, Ill.) according to the manufacturer’s recommendations, dried,
and exposed to autoradiography film without an enhancing screen. The products
of unlabeled reactions were used for Western analysis.
In vivo metabolic labeling with 32P and 35S. In vivo metabolic labeling of
uninfected and MCMV-infected NIH 3T3 cells with 32P was carried out as
previously described (9). Additionally, uninfected and MCMV-infected NIH 3T3
cells were metabolically labeled with 35S, using the same procedure as for 32P
labeling except that the medium, Dulbecco’s modified Eagle’s medium, lacked
methionine and cysteine (Gibco BRL) and was supplemented with 10% fetal
bovine serum and 1,500 mCi of 35S Translabel (ICN) per dish.
Immunoprecipitation and SDS-PAGE were carried out as previously de-
scribed (9) except that rabbit anti-GST-M83 serum was used for immunopre-
cipitation and a mini-SDS–10% polyacrylamide gel was used for separation. For
35S-labeled preparations, the gels were treated with Fluoro-Hance prior to flu-
orography.
Nucleotide sequence accession numbers. The GenBank accession number for
the nucleotide sequence of the M83 region of the K181 strain of MCMV is
U65003. The M82-M86 region of the Smith strain of MCMV has been assigned
GenBank accession number U68299.
RESULTS
Genomic localization of MCMV homologs of the HCMV
UL82 and UL83 proteins. The genomes of MCMV and
HCMV show striking colinearity, which we and others have
used to identify and clone the MCMV homologs of HCMV
genes of interest (Fig. 1A) (8, 9, 12, 41). This strategy led us to
target the HindIII C fragment of the MCMV genome as a
likely site for the MCMV homologs of the HCMV UL82 and
UL83 matrix proteins. Using the HindIII site at the junction of
the MCMV HindIII C and G fragments as a reference, we
identified five ORFs in the region of the Smith strain genome
(52) starting 3,487 bp from the HindIII site and extending
15,035 bp from the HindIII site (Fig. 1B). These ORFs are all
encoded by the same DNA strand, with the direction of tran-
scription proceeding away from the border of the HindIII C
and G fragments. The ORF furthest downstream from the
HindIII C/G junction is 598 amino acids and shows homology
to the HCMV UL82 protein. On the basis of this homology
and its relative position within the MCMV genome, this ORF
is designated M82. The next upstream ORF, 809 amino acids
in length, shows homology to the HCMV UL82 and UL83
proteins but is designated M83 on the basis of its relative
position within the MCMV genome. Upstream of M83 is an
ORF consisting of 587 amino acids. This ORF is designated
M84 on the basis of its relative position in the MCMV genome
but, as discussed below, shows substantial homology to both
the HCMVUL83 and UL84 proteins. The next ORF upstream
from M84 encodes a 311-amino-acid protein with substantial
homology to the HCMV UL85 and is designated M85. Finally,
the most upstream ORF is designated M86 and encodes a
potential product of 1,353 amino acids with homology to the
HCMV UL86 major capsid protein (52).
Analysis of M82, M83, and M84 ORF homologies and evo-
lutionary relationships. To determine the relationships be-
tween the M82, M83, and M84 ORFs and HCMV proteins, the
nonredundant protein database of GenBank was screened for
sequences related to the MCMV ORFs, using the FASTA
analysis program and scoring with the PAM250 scoring matrix
(49, 50). Table 1 summarizes the results of these analyses. For
M82, this analysis revealed a significant relationship with
UL82. The match between these two proteins was the closest
identified by FASTA in the database.
FASTA was also used to screen this database with the M83
ORF. The database was first screened by using the entire
809-amino-acid ORF. Homology with the HCMV UL82 was
detected. In this search also, the score assigned by FASTA for
this relationship with UL82 was the highest detected in the
database.
We noticed upon examination of homologies detected in the
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first search with M83 that much of the homology to UL82 was
localized to a repetitive acidic regions of the protein, located
between amino acids 425 and 447 and between amino acids 538
and 558 (Fig. 2). To eliminate the influence of these charged
repetitive regions, we repeated the search, using only the ami-
no-terminal 400 residues of the protein. With these parame-
ters, FASTA detected homology with the HCMV UL83 pro-
tein. While UL83 yielded the second-highest score in this
search, the best match was with UL82, in agreement with the
results of the previous search using the entire M83 ORF.
Searching the database by FASTA for proteins with homol-
ogy to M84 detected a number of HCMV homologs. Surpris-
ingly, the highest score was assigned to the match with the
HCMV UL83. Homology at a lower level was identified with
FIG. 1. (A) Comparison of the HindIII restriction maps of strain AD169 HCMV and strain K181 MCMV (39, 65). The approximate positions and transcriptional
directions of a number of representative homologous genes are indicated to demonstrate the relative colinearity of the two genomes. The locations of the M82 to M86
ORFs are indicated within the MCMV HindIII map. The MCMV M82 to M86 and HCMV UL82 to UL86 ORFs occur in numerical order as diagrammed. pol, DNA
polymerase; gB, glycoprotein B; gH, glycoprotein H; 2.2kb, HCMV 2.2-kb early transcription unit; M99, MCMVUL99 homolog; e1, MCMV early gene 1; pp89, MCMV
major immediate-early gene; IE1, IE2, immediate-early genes 1 and 2; MDBP, major DNA-binding protein. (B) Detailed localization of the M82 to M86 ORFs within
a 15.7-kbp HindIII-EcoRV subfragment of the HindIII fragment C. Arrows indicate the relative positions, sizes, and directions of the putative M82 to M86 ORFs. The
relative positions of important restriction endonuclease cleavage sites are also indicated. E, EcoRV; H, HindIII; K, KpnI; N, NotI; P, PstI; S, StuI. Distances in kilobase
pairs from the junction of the HindIII C and G fragments are indicated. The nucleotide positions for the various Smith strain ORFs are as follows (52): M82, 115714
to 117507; M83, 117617 to 120043; M84, 120085 to 121845; M85, 122192 to 123124; and M86, 123202 to 127260. All are on the complementary strand, with the genome
in the prototype orientation.
TABLE 1. Results of FASTA analyses
MCMV ORF Homologa % Identity Overlapb Scorec k-tuple
M82 UL82 18.6 360 182 2
M83d UL82 21.2 444 233 2
M83e UL82 22.4 343 210 2
M83e UL83 17.3 323 192 2
M84 UL83 20.6 325 208 1
M84 UL84 21.7 189 130 1
M84 U54 19.1 444 198 1
a All homologs are from HCMV (7) except U54, which is from human her-
pesvirus 6 (19, 36).
b Length of amino acid overlap identified by FASTA.
c Optimized FASTA score.
d The entire 807 amino acids of the K181 M83 ORF were used in this search.
e The N-terminal 400 amino acids of the K181 M83 ORF were used in this
search.
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UL84, as we had predicted on the basis of the colinearity of the
two genomes. However, the 189-amino-acid overlap identified
by FASTA in its comparison of M84 and UL84 was consider-
ably shorter than the 325-amino-acid overlap identified for the
comparison of M84 and UL83. The program also identified
fairly strong homology with U54 of human herpes virus 6, a
homolog of the HCMV UL82 and UL83 proteins (19, 36).
The results of these comparisons indicated to us that M82
was clearly related to the HCMV UL82. M83 appeared to
share homology with both the HCMV UL82 and UL83, with
the similarity to UL82 being somewhat greater. M84 appeared
to be a homolog of the HCMV UL83, although it also showed
modest homology with its positional homolog, UL84.
To confirm these hypothetical relationships and evaluate
their significance, we constructed a tree describing the phylo-
genetic lineage of these proteins. Analysis of the sequences
with the program inspect confirmed the relationships identified
above (data not shown) (11, 13, 14). With confirmation of the
hypothesized relationships, we used the program Progressive
Alignment to determine the best possible region and alignment
for the three HCMV and three MCMV ORFs. This program
selected 107-amino-acid overlaps from the six proteins and
calculated similarity scores and percent identity within the
overlaps (Fig. 3A). Branching order and branch distances were
next calculated by the program Tree, with the program noneg
correcting for negative branch distances (Fig. 3B). The result-
ant tree indicated that a common ancestor protein gave rise to
M82, M83, and M84 and to UL82, UL83, and UL84. UL84
appeared to be least related to the others, having been the first
to diverge from the putative ancestor protein. Among the
proteins derived from the putative cytomegalovirus matrix pro-
tein ancestor, M82 and M83 were most closely related to each
other, with their closest HCMV homolog being UL82. M84
was most closely related to UL83. On the basis of this and our
earlier analyses, we conclude that the likely MCMV homolog
of the HCMV UL83 protein is M84. The M83 and M82 pro-
teins appear to represent the murine homologs of the HCMV
UL82 protein, although the M83 is also related to the HCMV
UL83.
Transcriptional pattern in the M82-M86 region of HindIII
fragment C. To examine the pattern of transcription within this
region of the MCMV genome, we first examined the nucleic
acid sequence of the Smith strain (52) for the presence of
appropriate transcription control consensus sequences. TATA
sequences at positions consistent with their utilization for ini-
tiation of transcription in this region are present at appropriate
positions upstream of the five ORFs (Fig. 4A). Polyadenylation
signals are present at positions immediately before the start of
the M84 ORF, in the middle of the M82 ORF, and just down-
stream from the M82 ORF.
We next analyzed transcription in this region by Northern
(RNA) analysis. mRNA was harvested from uninfected or
MCMV-infected NIH 3T3 cells at 8, 24, and 48 h p.i. Northern
blots were prepared and probed with either oligonucleotide or
restriction fragment DNA probes (Fig. 4B). The oligonucleo-
tide probe 59M86, complementary to nucleotides at the 59 end
of the M86 ORF, detected transcripts of 5.7 and .9.5 kb at 24
and 48 h p.i. The second oligonucleotide probe, designated
59M85, is complementary to the coding strand at the 59 end of
the M85 ORF. It hybridized to four transcripts of 1.35, 5.7, 8,
and.9.5 kb at 24 and 48 h p.i. A double-stranded DNA probe,
designated M84, represented a restriction fragment encoding
the amino-terminal half of the M84 ORF. It hybridized faintly
to a transcript of 6.9 kb present only at 8 h p.i. and also to
transcripts of 8 and .9.5 kb at 24 and 48 h p.i. Probing North-
ern blots with oligonucleotide probes complementary to the
coding strand in the same region as the M84 probe yielded
identical results (data not shown). A third oligonucleotide
probe, designated 59M83, was located at the 39 end of the M84
FIG. 2. Derived amino acid sequence of the M83 ORF of the Smith strain of
MCMV. Extended stretches of acidic residues are underlined.
FIG. 3. Derived phylogenetic relationships between the MCMV M82, M83,
and M84, and HCMV UL82, UL83, and UL84 proteins. (A) Alignment of
regions identified by Progressive Alignment (11, 13, 14). This program selected
the following residues for alignment: in HCMV, 268 to 374 for UL82, 257 to 360
for UL83, and 409 to 510 for UL84; in MCMV, 272 to 373 for M82, 259 to 361
for M83, and 253 to 356 for M84 (23, 63). Gap penalty was set at a value of 8,
and the PAM250 scoring matrix was used. (B) Phylogenetic tree derived by Tree
from the alignments identified in panel A after correction for negative branch
distance values by noneg. Branch distances in arbitrary units of evolutionary
distance are indicated.
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ORF, just 59 of the M83 ORF. It hybridized to transcripts of 5,
8, and .9.5 kb at 24 and 48 h p.i. With longer exposures,
hybridization to a 6.9-kb transcript was also observed at 8 h p.i.
A double-stranded DNA probe, designated M82, represented
a 682-bp StuI-PstI fragment from the 39 end of the M82 ORF.
This probe detected a 6.9-kb transcript at 8 h p.i. and tran-
scripts of 2.2, 3.5, 5, 8, and .9.5 kb at 24 and 48 h p.i., with the
3.5-kb transcript likely arising from the antisense strand. Oli-
gonucleotide probes complementary to the M82 ORF detected
identically sized transcripts, other than the 3.5-kb species (data
not shown). Finally, an oligonucleotide probe, designated
39M82, which was complementary to a region 39 of the most
downstream polyadenylation signal, failed to hybridize with
any transcripts (data not shown).
On the basis of the location of transcriptional control se-
quences in relation to the various ORFs and the transcript
sizes observed in Northern analysis, we deduced a likely tran-
scription pattern for this region (Fig. 4A). The initiation of 5.7-
and 12-kb transcripts, the latter of which appeared as .9.5 kb
in Northern blots, is directed by the TATA box located 59 of
the M86 ORF, with termination occurring at the polyadenyl-
ation signals just 59 of the M84 ORF and 39 of the M82 ORF,
respectively. These transcripts likely encode the M86 gene
product and are synthesized with kinetics consistent with late
gene expression. Transcripts of 1.35 and 8 kb are directed by
the TATA box located at the 39 end of the M86 ORF, just 59
of the M85 ORF, and extend to the polyadenylation signals just
59 of the M84 ORF and 39 of the M82 ORF, respectively.
These transcripts, which exhibit late gene kinetics, appear to
encode the M85 gene product. A 6.9-kb transcript is directed
by either of two TATA boxes located just 59 of the M84 ORF,
extending to the polyadenylation signal located 39 of the M82
ORF. This transcript likely encodes the M84 ORF product and
is detectable only at 8 h p.i., consistent with early gene kinetics.
However, we cannot exclude the possibility that the M84 pro-
tein is also translated from the .9.5- or 8-kb late transcripts
which initiate upstream of the M86 and M85 ORFs, respec-
tively. A 5-kb transcript with late kinetics is directed by the
TATA box located 59 of the M83 ORF, within the M84 ORF.
It extends to the polyadenylation signal 39 of the M82 ORF and
encodes the M83 protein. Finally, a transcript of 2.2 kb is
directed by the TATA box just 59 of the M82 ORF and extends
to the polyadenylation signal 39 of this ORF. This transcript
likely encodes the M82 gene product and displays late gene
kinetics.
Although a potential polyadenylation signal is present in the
middle of the M82 ORF (Fig. 4A), data from S1 nuclease
protection experiments indicated that this site is not utilized
(data not shown). Instead, the polyadenylation signal 39 of this
ORF is used by all transcripts that extend to it. This finding
agrees with the results of Northern analysis, which showed that
the oligonucleotide probe 39M82 failed to hybridize to any
transcripts.
Humoral immunogenicity of the M82, M83, and M84 ORF
products during natural MCMV infection. We next assessed
the development of humoral immune responses against the
M82, M83, and M84 ORF protein products in MCMV-in-
fected mice (Fig. 5). These ORFs and the DNA encoding the
MCMV pp89 immediate-early protein were cloned into the
plasmid pcDNA3, allowing expression of the encoded proteins
by coupled in vitro transcription-translation. The proteins were
produced either in the presence or in the absence of 35S-
labeled amino acids, allowing direct detection of the labeled
translation products or Western analysis of the unlabeled
products.
In the labeled reactions, pcDNA3-M82 yielded species of 77
and 61 kDa, with the 77-kDa product being somewhat larger
than the 67 kDa predicted by the M82 primary amino acid
sequence (Fig. 5A). pcDNA3-M83 yielded major products with
calculated molecular masses of 113 and 97 kDa. While larger
FIG. 4. Northern analysis of M82-M86 region of MCMV HindIII fragment
C. (A) Diagram of the M82-M86 region of the MCMV HindIII fragment C, with
the positions of the various ORFs, TATA sites, polyadenylation signals (PolyA
Signals), probes, and putative transcripts indicated. The relative positions of
TATA signals are indicated, with arrows indicating the direction of transcription.
Polyadenylation signals are indicated with arrows pointing in the direction op-
posite the direction of transcription. The relative positions of oligonucleotide
probes complementary to the coding strand are indicated and labeled (59M86,
59M85, 59M83, and 39M82). The relative locations and approximate sizes of
double-stranded DNA probes are indicated by hatched boxes and labeled (M84
and M82). The relative positions, sizes, and predicted products of the various
transcripts are indicated. (B) Northern blots were prepared from polyadenylated
or total and polyadenylated (M82; indicated by T or A above the appropriate
lane) RNA from uninfected NIH 3T3 cells (Uninf) or MCMV-infected NIH 3T3
cells at 8, 24, and 48 h p.i. The blots were probed with either an oligonucleotide
probe complementary to the region at the 59 end of the M86 ORF (59M86), at
the 59 end of the M85 ORF (59M85), or just 59 of the beginning of the M83 ORF
(59M83) or with double-stranded DNA probes complementary to regions within
the M84 and M82 ORFs (labeled M84 and M82, respectively).
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than the 91 kDa predicted by the amino acid sequence, the size
of the larger species approximates that of the authentic pro-
tein, as we demonstrate below. pcDNA3-M84 yielded three
major species of 66, 61, and 56 kDa. The largest species ap-
proximates the 65-kDa size predicted by the amino acid se-
quence. Finally, pcDNA3-pp89 yielded a single major product
of approximately 89 kDa.
In parallel with the labeled translations, the same plasmids
were used in unlabeled in vitro transcription-translation reac-
tions to allow examination of the humoral immunogenicity of
the ORF products in natural infection. A Western blot of the
unlabeled in vitro-translated proteins was probed with anti-
MCMV hyperimmune serum (Fig. 5B). As expected, the major
89-kDa species produced from pcDNA3-pp89 was strongly
recognized by hyperimmune serum. Of the three putative ma-
trix protein ORFs, only the major product of the M83 ORF, at
113 kDa, was clearly detectable. There was an increased band
intensity in the M82 lane at a position approximating the lo-
cation of the 77-kDa species, but comigrating immunoreactive
species are present in the pcDNA3 negative control. Normal
mouse serum failed to detect any of these proteins (data not
shown). We cannot exclude the presence of antibodies directed
against M82 or M84, but such antibodies are likely to be
present only at low levels, if at all.
To confirm the presence of M83-specific antibodies in in-
fected mouse serum, serum from MCMV-infected or unin-
fected BALB/c mice was adsorbed with an acetone powder
derived from a culture of pGEX-KG-containing E. coli in-
duced to produce large amounts of GST protein (22). This
removed any fortuitous immunoreactivities against GST. The
adsorbed sera were then used to probe Western blots contain-
ing various amounts of purified preparations of GST or GST-
M83, the latter of which encodes a fusion protein containing
the N-terminal 669 amino acids of M83. As expected, both
normal and hyperimmune mouse sera showed no reactivity
against GST, confirming that any antibodies detected were
directed against M83 epitopes of the fusion protein (Fig. 6).
Hyperimmune mouse serum demonstrated dose-dependent
immunoreactivity against GST-M83, recognizing immunoreac-
tive species of 121, 114, and 82 kDa (Fig. 6A). These proteins
are somewhat larger than the predicted size of 94 kDa, likely
because of the presence of strongly acidic regions encoded by
the ORF. In contrast, uninfected mouse serum detected no
immunoreactive species (Fig. 6B). We conclude that BALB/c
mice are capable of mounting a humoral response against the
MCMV M83 protein and do so in the course of MCMV in-
fection.
Analysis of the derived M83 amino acid sequence. In view of
the strong humoral response generated against the M83 pro-
tein following MCMV infection, we characterized the protein
product of this ORF in detail. The derived amino acid se-
quence of this protein exhibits a number of interesting details
(Fig. 2). The 809-amino-acid ORF of the Smith strain of
MCMV, which encodes a protein with a predicted molecular
mass of 90,837 Da, has an unusually high content of charged
amino acids, comprising 30% of the protein (245 of 809 resi-
dues). Of particular note is the presence of two stretches of 23
and 21 contiguous acidic residues (residues 425 to 447 and 538
to 558, respectively). Within the M83 protein are a number of
potential protein kinase target motifs, including those for pro-
tein kinase C, casein kinases I and II, and tyrosine kinases (37).
Additionally, amino acid residues capable of phosphorylation
(serine, threonine, and tyrosine) comprise a large fraction (114
of 809 amino acids) of the ORF. These may serve as target
sites for other protein kinases.
We have sequenced both strands of the M83 ORF of the
K181 strain of MCMV (12). The M83 of K181 encodes an
807-amino-acid protein with a calculated molecular mass of
90,578 Da. Comparison of the derived amino acid sequence
with that of the Smith strain reveals relatively strong sequence
conservation, with differences being limited essentially to the
acidic regions of the protein. The K181 M83 possesses an
insertion of a glutamate between residues 424 and 425 and a
deletion of residues 544 to 546 (Glu-Glu-Asp). The K181 M83
FIG. 5. Humoral responses against M82, M83, and M84 proteins in infection
of BALB/c mice with MCMV. Plasmids containing ORFs encoding the M82,
M83, M84, and pp89 proteins of MCMV and the plasmid vector pcDNA3 alone
were translated in vitro with (A) or without (B) 35S-labeled methionine. The
translation products were then separated by SDS-PAGE. Gels containing labeled
preparations were then stained, dried, and fluorographed. Gels containing un-
labeled preparations were transferred to nitrocellulose and assayed by Western
blot analysis with BALB/c mouse anti-MCMV hyperimmune serum as the probe
as described in Materials and Methods. The ORF translated from each substrate
plasmid is indicated above each lane. The positions of molecular mass markers
are indicated.
FIG. 6. Humoral immunogenicity of the MCMV M83 following infection of
BALB/c mice. Various amounts of purified GST or GST-M83 were separated on
mini-SDS–10% polyacrylamide gels and analyzed by Western blotting, using a
1:200 dilution of either mouse anti-MCMV hyperimmune serum (A) or normal
mouse serum (B). The sera had been previously adsorbed with an acetone
powder made from pGEX-KG-containing E. coliDH5a following induction. The
positions of GST and GST-M83 fusion proteins and molecular mass markers (in
kilodaltons) are indicated.
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has substitutions of a glutamate for an aspartate at residue 549,
an aspartate for a glutamate at residue 551, and an aspartate
for a glutamine at residue 562.
Pattern of protein expression, virion association, and in vivo
phosphorylation state of the MCMV M83. The kinetics of
expression of the M83 protein were examined by Western
analysis of MCMV-infected NIH 3T3 cells harvested at 8, 24,
or 48 h p.i., using rabbit anti-GST-M83 antiserum as the probe.
Immunoreactive proteins of approximately 125, 105, and 70
kDa are detectable by Western blotting only at 48 h p.i. (Fig.
7A). This finding suggests that the M83 ORF is a member of
the late class of viral genes. In the same experiment, NIH 3T3
cells were infected with MCMV either in the presence of
cycloheximide, limiting protein expression to viral immediate-
early genes, or in the presence of phosphonoacetic acid, lim-
iting protein expression to viral immediate-early and early
genes. Species immunoreactive with anti-GST-M83 antiserum
are detectable only at 48 h p.i. in the absence of metabolic
inhibitors, thereby classifying the M83 ORF as a member of
the true late class of viral genes. Such a classification agrees
with the pattern of transcription of this gene, with its putative
5-kb mRNA being expressed only at 24 to 48 h p.i. The absence
of detectable protein at 24 h p.i., despite the presence of the
M83 transcript at this time, is likely due to the level of protein
expression being below the limit of detection of the Western
blot.
To investigate the virion association of the M83 proteins, we
purified virions from the tissue culture supernatant of MCMV-
infected NIH 3T3 cells. Virions were first pelleted by centrif-
ugation and then purified further by sucrose gradient sedimen-
tation (9). When analyzed by Western blotting using anti-GST-
M83 antiserum as the probe, a major immunoreactive protein
of 125 kDa and a minor one of 105 kDa are detectable in the
material pelleted from infected tissue culture supernatant (Fig.
7B). The 125-kDa band was also detected when the virus was
further purified by sucrose gradient sedimentation. These data
indicate that the M83 protein is virion associated, with the
125-kDa species being the major form of the protein in the
virus particle.
To examine the in vivo phosphorylation state of the M83
gene product, uninfected or MCMV-infected NIH 3T3 cells
were labeled at 46 to 48 h p.i. with 35S or 32P, and total proteins
were harvested and subjected to immunoprecipitation with
either the anti-GST-M83 antiserum or preimmune serum.
SDS-PAGE and fluorography of 35S-labeled proteins revealed
the production of proteins of 125, 70, and 60 kDa that are
specifically immunoprecipitated by the anti-GST-M83 serum
from virally infected cells (Fig. 8A). Immunoprecipitation from
32P-labeled cells indicated that only the 125- and 70-kDa spe-
cies are detectably phosphorylated (Fig. 8B). We conclude that
the M83 protein exists in vivo in a phosphorylated state, con-
sistent with the presence of numerous potential protein kinase
target motifs within the primary amino acid sequence.
We believe that the 125-kDa form of the M83 protein is the
major product of this ORF. The discrepancy in size between
the apparent molecular mass by SDS-PAGE and the calculated
molecular mass of about 91 kDa can be accounted for by the
extensive acidic regions in the M83 amino acid sequence and
also by phosphorylation of the protein, both of which will tend
to retard the protein’s migration in SDS-PAGE. Lower molec-
ular mass products are possibly the result of either proteolytic
degradation or posttranslational processing of the protein.
Construction of recombinant vaccinia viruses expressing
the M83 ORF. In preparation for studies of the protective
efficacy of M83 in experimental vaccination, we constructed a
recombinant vaccinia virus (M83-vacc) expressing this protein.
Additionally, we constructed a recombinant vaccinia virus ex-
pressing b-galactosidase (pSC11-vacc) as a negative control.
The products of these vaccinia viruses were analyzed by West-
ern blotting of infected NIH 3T3 cells, alongside uninfected or
MCMV-infected NIH 3T3 cells. Probing a Western blot of
M83-vacc-infected NIH 3T3 cells with the anti-GST-M83 an-
tiserum revealed production of a major immunoreactive prod-
uct that comigrates with a MCMV-specific protein of about
125 kDa (Fig. 9). Similar results were obtained with the anti-
MCMV hyperimmune serum (data not shown). Additionally, a
number of smaller comigrating products are evident in both
cases, albeit in lower relative amounts in M83-vacc-infected
cells. No immunoreactive species is detectable in extracts of
cells infected with pSC11-vacc, the b-galactosidase-expressing
FIG. 7. Properties of the M83 protein. (A) Gene class and time course of
expression. NIH 3T3 cells were infected with the K181 strain of MCMV with or
without additional metabolic inhibitors. Cells infected in the absence of inhibi-
tors were harvested at 8, 24, and 48 h p.i. Cells were also infected in the presence
of cycloheximide for 8 h, washed to remove the drug, and harvested at 12 h p.i.
(CHX) or were infected in the presence of phosphonoacetic acid and harvested
at 48 h p.i. (PAA). The proteins were separated on an SDS–7.5% polyacrylamide
gel and analyzed by Western blotting, using rabbit anti-GST-M83 antiserum as
probe. Positions of molecular mass markers are indicated. (B) Virion association.
Supernatant from MCMV-infected or uninfected NIH 3T3 cells was pelleted by
ultracentrifugation (Hard Spin 6 MCMV). Pelleted material from infected cell
cultures was subjected to further purification by centrifugation through a sucrose
gradient (Purified). The resulting preparations were separated on mini-SDS–
10% polyacrylamide gels and subjected to Western analysis, using rabbit anti-
GST-M83 antiserum as the probe. Positions of molecular mass markers are
indicated.
FIG. 8. In vivo labeling with 35S (A) and 32P (B). Uninfected (Uninf) and
MCMV-infected (Inf) NIH 3T3 cells were labeled at 46 to 48 h p.i. with 35S or
32P. Total proteins were harvested from these cells and immunoprecipitated with
either preimmune (Preimm) or immune (Imm) rabbit anti-GST-M83 antiserum.
Immunoprecipitated material was separated on mini-SDS–10% polyacrylamide
gels and fluorographed (35S) or autoradiographed (32P). Arrows indicate the
sizes of proteins specifically precipitated from infected cell extracts by anti-GST-
M83 antiserum. Positions of molecular mass markers are indicated.
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negative control virus. Differences in relative amounts of dif-
ferent species in the MCMV-infected cells, compared with
those in other blots (Fig. 7A), are likely attributable to the
different extraction protocols used.
Production of a protein by M83-vacc that comigrates with
and is serologically cross-reactive with the major 125-kDa band
in MCMV-infected cells supports the contention that M83-
vacc expresses the authentic M83 protein. It also provides
additional evidence for lack of splicing within the M83 tran-
script, since vaccinia virus, with its cytoplasmic replication
scheme, cannot mediate splicing (42, 43). The vaccinia virus-
expressed product comigrates with the authentic M83 protein
despite the fact that the latter exhibits aberrant migration in
SDS-PAGE, indicating that the two proteins must possess sim-
ilar biophysical properties. We cannot exclude the possibility of
a small splicing event which alters the size of the protein at a
level undetectable in this analysis but maintains the reading
frame.
DISCUSSION
We show here that the MCMV genome has continued to
maintain its global colinearity with the HCMV genome with
respect to the apparent MCMV homologs of the HCMVUL82
and UL83 proteins. However, the local organization of the
MCMV homologs appears to be somewhat different. As pre-
dicted, the MCMV M84 ORF shows some homology to its
colinear HCMV counterpart, UL84. Unexpectedly, however,
M84 shows even stronger homology to the HCMV UL83 ma-
trix protein. The relationship of M84 to matrix proteins is
further supported by its relatively strong homology with U54 of
human herpesvirus 6, which also has homology with UL82 and
UL83 and is thus believed to be a matrix protein (19, 36).
Moreover, our analysis of the phylogenetic relationship of
these proteins provides additional evidence for the close rela-
tionship between M84 and UL83.
The HCMV UL84 is a nonstructural early protein which has
been shown to interact with the HCMV immediate-early pro-
tein IE86 (23, 66). UL84 is also required in the complemen-
tation assay for replication of a plasmid containing the HCMV
origin of replication (25, 48). Interestingly, the 6.9-kb tran-
script, which likely encodes the M84 product, is detectable only
at 8 h p.i., consistent with early gene expression. This parallels
the transcription pattern of UL84. UL83 shows somewhat dif-
ferent kinetics of expression, being an early-late gene (10, 16).
As we noted earlier, M84 could potentially be synthesized from
the 8- or .9.5-kb transcripts synthesized at 24 to 48 h p.i.,
potentially making it a member of the early-late or true late
gene class. This could perhaps occur through a mechanism
involving internal initiation of translation, a mechanism that
has been identified for other cytomegalovirus proteins, includ-
ing the UL32 (pp150) matrix phosphoprotein (2). Generation
of an M84-specific antiserum should allow more precise defi-
nition of the temporal expression kinetics and localization. On
the basis of homology to known structural components of
HCMV, we predict that M84 is virion associated. At present,
we can only speculate that M84 may represent a hybrid pro-
tein, serving functions for MCMV carried out by both of its
apparent HCMV homologs.
MCMV has two apparent homologs of the HCMV UL82,
M82 and M83, possibly due to a duplication event at some
point during the evolutionary history of MCMV after it di-
verged from HCMV. It is important to note that these rela-
tionships are not absolute, as M83 shows detectable homology
to the HCMV UL83, indicating that M83 may represent a type
of hybrid between the HCMV UL82 and UL83 proteins. Our
analysis of the phylogenetic relationships of the various
MCMV and HCMV proteins nevertheless supports the close
relationship between M82, M83, and the HCMV UL82.
When we initiated our studies of the transcription pattern
for the M82 to M86 ORFs, we found that the presence of
overlapping transcripts of various sizes, some quite large, in-
terfered with attempts to analyze mRNA expression through
the use of primer extension and nuclease protection assays.
However, Northern analysis, coupled with analysis of the DNA
sequence for transcriptional control consensus sequences, al-
lowed us to decipher a likely pattern of transcription. There is
good agreement in our transcriptional model between the pre-
dicted and observed sizes of the transcripts, suggesting an
absence of large-scale splicing events. However, we cannot
exclude the possibility of small splicing events, which would not
be reflected as detectable changes in transcript size in North-
ern analysis. Such a splicing event has been observed in UL83
of the Towne, but not of the AD169, strain of HCMV (46, 47).
In that case, however, the splice maintains the predicted read-
ing frame.
Of the three putative MCMV matrix proteins, only the M83
product is the target of an easily detectable humoral immune
response, as are its putative HCMV counterparts, the HCMV
UL82 and UL83 (4). Although antibodies directed against
MCMV matrix proteins, like those against HCMV matrix pro-
teins, are likely nonneutralizing and nonprotective, their de-
tection may be useful as a serological marker of the infection
(18, 61). If the immune response against these matrix proteins
can be protective, we predict that it will be so through the
induction of cellular responses, specifically through CTLs.
The M83 gene product shows a number of properties con-
sistent with its proposed identity as an MCMV homolog of the
HCMV UL82 protein (62). Specifically, it is virion associated
and phosphorylated in vivo. While neither of these properties
clearly identifies this protein as being the MCMV homolog of
the HCMV UL82 protein, they are both properties of matrix
proteins of HCMV. Additionally, M83 is a true late protein, as
are all known HCMV matrix components other than UL83
(10, 16, 26, 40, 44, 63). These properties of M83 support its
putative identification.
When we compared the amino acid sequences of the M83
proteins of the Smith and K181 strains of MCMV, we found
that the differences were minor and limited to the repetitive
acidic regions of the protein. However, the variability is suffi-
cient for potential use as a strain-specific marker in experi-
ments involving the introduction of viruses of both strains into
the same tissue culture or experimental animal.
In summary, we have analyzed the potential protein coding
FIG. 9. Expression of M83 protein by recombinant vaccinia virus. Lysates of
NIH 3T3 cells uninfected or infected with the recombinant vaccinia virus M83-
vacc or pSC11-vacc or MCMV were separated on mini-SDS–10% polyacryl-
amide gels and transferred to nitrocellulose for Western analysis using rabbit
anti-GST-M83 antiserum as the probe. The arrow indicates the position of the
major species present in both M83-vacc- and MCMV-infected cells. Positions of
molecular mass markers are indicated at the left.
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content of a portion of the MCMV HindIII C fragment, con-
taining ORFs corresponding to the apparent MCMV ho-
mologs of the HCMV UL82 and UL83 matrix phosphopro-
teins. MCMV has three apparent matrix protein ORFs: M84,
encoding an HCMV UL83/UL84 homolog; M83, encoding a
UL82/UL83 homolog; and M82, encoding a UL82 homolog.
We found that only M83 is the target of an easily detectable
immune response in natural infection, and it exhibits kinetic
properties, virion association, and in vivo phosphorylation con-
sistent with its identification as a matrix protein. These results
provide a starting point for detailed characterization of the
immunological roles played by matrix proteins in MCMV in-
fection. By analogy, such analyses may provide us with deeper
insights into the immunology of HCMV, as have previous
studies in the mouse model.
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